Daily Cardiology Research Analysis
Analyzed 89 papers and selected 3 impactful papers.
Summary
Across cardiology, three studies stand out: a 365,771-participant UK Biobank analysis shows apolipoprotein B and lipoprotein(a) outperform LDL-C for sex-specific aortic stenosis risk assessment; a real-world target trial emulation suggests GLP-1 receptor agonists reduce mortality, myocardial infarction, and heart failure hospitalizations in ASCVD with obesity but without diabetes; and a multi-omics study in young patients delivers high-accuracy diagnostic models and implicates a microbiota–metabolism–immunity network in coronary disease.
Research Themes
- Advanced lipid biomarkers for sex-specific aortic stenosis risk stratification
- GLP-1 receptor agonists for secondary prevention in ASCVD with obesity without diabetes
- Multi-omics and microbiome-driven diagnostics in early-onset coronary disease
Selected Articles
1. Moving beyond Low-Density Lipoprotein cholesterol: apolipoprotein B and Lipoprotein (a) for sex-specific risk assessment of aortic stenosis in the UK Biobank.
In 365,771 UK Biobank participants over 13.8 years, apoB outperformed LDL-C for associating with incident aortic stenosis, and adding Lp(a) further improved discrimination, especially in men. No lipid traits were associated with aortic regurgitation, supporting a sex-specific, multi-biomarker strategy for AS risk assessment.
Impact: This very large, prospective analysis redefines lipid-based risk stratification for aortic stenosis by elevating apoB and Lp(a) over LDL-C and introduces a sex-specific framework with immediate implications for preventive cardiology.
Clinical Implications: Consider apoB as the primary atherogenic particle marker and routinely measure Lp(a) to refine AS risk assessment, particularly in men; integrate these markers into sex-specific risk models to guide surveillance and preventive trials.
Key Findings
- ApoB outperformed LDL-C in association with incident aortic stenosis across sexes.
- Lp(a) independently predicted AS risk and improved discrimination when added to ApoB or LDL-C, with a stronger effect in men (Pinteraction=0.004).
- No lipid trait was associated with aortic regurgitation.
- Hierarchical clustering placed Lp(a) on an independent branch separate from apoA- and apoB-containing clusters.
Methodological Strengths
- Very large prospective cohort (N=365,771) with long follow-up (median 13.8 years).
- Sex-stratified Cox models, discordance analyses, and time-dependent C-index for robust comparative assessment.
Limitations
- Observational design limits causal inference and residual confounding cannot be excluded.
- UK Biobank volunteer bias may restrict generalizability to more diverse populations.
Future Directions: External validation in diverse cohorts and incorporation of apoB and Lp(a) into AS risk calculators; interventional trials targeting Lp(a) and particle burden to assess effects on AS onset and progression.
BACKGROUND AND AIMS: Lipid abnormalities-particularly low-density lipoprotein cholesterol (LDL-c) and lipoprotein(a) [Lp(a)]-have been implicated in aortic stenosis (AS), yet translation into clinically actionable risk assessment remains underdeveloped, especially regarding sex-specific evaluation. This study aims to quantify sex-specific associations between a comprehensive lipid profile and the risks of AS and aortic regurgitation (AR), and to identify the most informative markers and marker combinations for improved risk assessment. METHODS: In 365,771 UK Biobank participants (mean age 56.1±8.07 years; 55.74% female) free of baseline cardiovascular disease. Routine lipid traits underwent hierarchical clustering and were related to incident AS and AR using sex-stratified Cox models. Discordance analyses and time-dependent concordance index were employed to compare risk assessment performance of different markers. RESULTS: Hierarchical clustering revealed three clusters in both sexes-an apolipoprotein B (apoB)-containing cluster and an apolipoprotein A containing cluster-while Lp(a) occupied an independent branch. During a median follow-up of 13.8 years, there were 3118 incident AS and 1239 AR cases. Total cholesterol, apoB, LDL-c, non-high-density lipoprotein cholesterol in apoB-containing cluster and Lp(a) were each independently associated with higher AS risk in both sexes (all P < 0.01), with Lp(a) conferred additional sex-specific effect (P for interaction = 0.004). Discordance analyses showed that apoB outperformed LDL-c in association with AS. Addition of Lp(a) to ApoB or LDL-c improved AS risk prediction over either marker alone-especially in men. No lipid trait was associated with AR. CONCLUSION: ApoB may substitute for LDL-c as the primary particle-burden marker, whereas Lp(a) should be incorporated as an independent sex-specific risk enhancer in AS risk assessment. These results support sex-specific, multi-biomarker assessment to optimize AS risk stratification and future preventive strategies. In 365,771 UK Biobank participants followed for a median of 13.8 years, apoB and Lp(a) improved identification of incident aortic stenosis risk compared with LDL-C alone. Incorporating Lp(a) into models with apoB or LDL-c improves AS risk discrimination, especially in men. ApoB outperforms LDL-c for AS risk assessment in both men and women.Elevated Lp(a) significantly increases AS risk, with a stronger effect in men.
2. Multi-omics landscape and machine learning predictors of acute and chronic coronary syndrome diagnosis in young patients.
In 206 young chest-pain patients, integrating transcriptomics, serum/stool metabolomics, and gut metagenomics produced high-accuracy diagnostic models (AUC 0.95–0.99) distinguishing ACS and CCS subtypes and implicated a microbiota–metabolism–immunity axis. Streptococcus parasanguinis was validated as a pro-atherogenic microbe in mice.
Impact: This translational multi-omics study delivers near-clinical diagnostic performance in a high-need young population and uncovers microbial and metabolic contributors, opening avenues for precision diagnostics and targeted interventions.
Clinical Implications: If externally validated, multi-omics fusion models could augment ED and clinic triage of young chest-pain patients and identify mechanistic targets (e.g., microbiota modulation) for prevention and therapy.
Key Findings
- Single-omics layers were insufficient, while multi-omics integration achieved AUCs of 0.99 (ACS vs NACS), 0.95 (CCS vs NC), and 0.96 (STEMI vs NSTE-ACS).
- Distinct metabolic and inflammatory signatures characterized subtypes; STEMI linked to amino acid/carbohydrate dysregulation and inflammatory pathways.
- Streptococcus parasanguinis emerged as a biomarker and was validated as a pro-atherogenic agent in a murine model.
- A comprehensive diagnostic pipeline integrating multi-omics was developed for young CHD.
Methodological Strengths
- Integrated multi-omics across transcriptome, serum/stool metabolome, and gut metagenome with machine learning fusion.
- Cross-species validation of a candidate microbe (S. parasanguinis) in a murine model.
Limitations
- Single-center, modest sample size increases risk of overfitting; external validation is lacking.
- Cross-sectional design limits causal inference; clinical utility depends on prospective deployment studies.
Future Directions: Prospective, multi-center external validation with real-time pipelines; interventional studies targeting identified microbial/metabolic nodes; cost-effectiveness and implementation studies.
BACKGROUND: Acute coronary syndrome (ACS) is a leading global cause of death, and its incidence is increasingly rising in young adults, who exhibit distinct clinical characteristics from elderly patients. However, multi-omics studies focusing specifically on young coronary heart disease (CHD) patients remain scarce, hindering precise diagnosis and mechanism exploration. METHODS: Here, we enrolled 206 young chest pain patients (18-45 years old), including 122 ACS patients, 38 chronic coronary syndrome (CCS) patients, and 46 individuals with healthy coronary arteries (NC). We performed integrated analyses of peripheral blood mononuclear cell transcriptomics, serum metabolomics, stool metabolomics, and gut microbiome metagenomics to characterize CHD subtypes and develop targeted diagnostic tools. RESULTS: Our results showed that single omics layers had limited ability to distinguish CHD subtypes, while multi-omics integration significantly improved diagnostic efficacy. We identified unique molecular signatures for different subtypes: STEMI was associated with abnormal amino acid and carbohydrate metabolism, CCS was dominated by amino acid metabolism disturbances, and both STEMI and ACS showed enriched inflammation-related pathways. Novel biomarkers including p-chlorobenzene sulfonamide, cotinine, and the gut bacterium Streptococcus parasanguinis were identified, with Streptococcus parasanguinis validated as an atherogenic pathogen in a murine model. We constructed three multi-omics fusion diagnostic models (ACS vs. NACS, CCS vs. NC, STEMI vs. NSTE-ACS) with AUC values of 0.99, 0.95, and 0.96, respectively, and integrated them into a comprehensive diagnostic pipeline. Furthermore, multi-omics functional analysis unraveled a synergistic "microbiota-metabolism-immunity" regulatory network underlying CHD subtypes, linked to disordered amino acid and carbohydrate metabolism and aberrant inflammatory activation. CONCLUSION: This study provides a systematic molecular landscape of young CHD, a high-precision diagnostic strategy, and novel targets for mechanism research and targeted intervention, addressing the unmet clinical need for precise management of young CHD patients.
3. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Obesity Without Diabetes.
In a target trial emulation of 14,844 matched ASCVD patients with overweight/obesity but without diabetes, GLP-1 RAs were associated with lower all-cause mortality, myocardial infarction, and heart failure hospitalization over 5 years, with no significant effect on stroke. Results align directionally with SELECT and extend across GLP-1 RA agents.
Impact: Provides robust real-world evidence across multiple GLP-1 RAs in a non-diabetic ASCVD population, reinforcing cardiometabolic therapeutic strategies beyond glycemic control.
Clinical Implications: For ASCVD patients with overweight/obesity but without diabetes, consider GLP-1 RAs to reduce mortality and cardiovascular events alongside guideline-directed therapy, while awaiting confirmatory randomized data.
Key Findings
- GLP-1 RA initiation was associated with lower all-cause mortality (HR 0.68; 95% CI 0.53–0.88).
- Reduced acute myocardial infarction (sHR 0.63) and heart failure hospitalization (sHR 0.61); stroke not significantly reduced.
- Findings were consistent in landmark and age subgroups and in sensitivity analysis including patients with diabetes.
Methodological Strengths
- Target trial emulation with large-scale propensity matching and balance (TriNetX network).
- Competing risk modeling (Fine-Gray) and multiple sensitivity/landmark analyses.
Limitations
- Observational design susceptible to residual confounding and treatment selection bias.
- Heterogeneity across GLP-1 RA agents and reliance on coding accuracy in EHR data.
Future Directions: Randomized trials across GLP-1 RA agents in non-diabetic ASCVD with obesity; mechanistic studies (weight loss, inflammation, hemodynamics); cost-effectiveness and implementation research.
The Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) trial demonstrated cardiovascular benefits of semaglutide in patients with obesity without diabetes; however, the real-world effect across multiple GLP-1 receptor agonist (GLP-1 RA) agents in patients with established atherosclerotic cardiovascular disease (ASCVD) and overweight or obesity without diabetes mellitus remains unknown. We conducted a target trial emulation using data from the TriNetX US Collaborative Network (January 1, 2010-December 1, 2025) in adults aged ≥45 years with established ASCVD (history of myocardial infarction, stroke, or coronary or peripheral revascularization), BMI ≥27 kg/m², and without type 2 diabetes. New initiation of any GLP-1 RA (liraglutide, semaglutide, dulaglutide, or exenatide) was compared with no GLP-1 RA use. The primary outcome was all-cause mortality; secondary outcomes were acute myocardial infarction, stroke, and heart failure hospitalization over 5 years, analyzed using Cox proportional hazards and Fine-Gray subdistribution hazard models to account for the competing risk of death. Among 14,844 propensity-matched patients without diabetes (7,422 per group; median age 63 [IQR 55-71] years; 64% women), GLP-1 RA use was associated with lower all-cause mortality (HR 0.68; 95% CI 0.53-0.88; P=.003), acute myocardial infarction (sHR 0.63; 95% CI 0.41-0.98; P=.040), and heart failure hospitalization (sHR 0.61; 95% CI 0.39-0.95; P=.028); no significant association was observed for stroke (sHR 0.76; 95% CI 0.52-1.10; P=.146). Findings were consistent in landmark and age subgroup analyses; a sensitivity analysis including patients with diabetes (N=31,910 matched pairs) showed similar associations. In conclusion, these real-world findings are broadly directionally consistent with the SELECT trial and provide complementary observational evidence across multiple GLP-1 RA agents in patients with established ASCVD and overweight or obesity without diabetes mellitus, though causal inference cannot be established from observational data alone.